Evidence map›Paper›PMID 40396679›Full record

ArticleAmerican journal of hematology2025

PET/CT in the Staging and Treatment Response Assessment of Patients With Extranodal Marginal Zone Lymphoma.

Juan Pablo Alderuccio, Russ A Kuker, Eduardo Edelman Saul, Michele D Stanchina, Mark K Polar, Jennifer Chapman, Wei Zhao, Rafael Hennemann Sassi, Craig H Moskowitz, Isildinha M Reis and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. CXCR4-targeted [European journal of nuclear medicine and molecular imaging · 2026
    Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Juan Pablo AlderuccioDivision of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA.ORCID 0000-0002-2690-3377
Russ A KukerDivision of Nuclear Medicine, Division of Radiology, University of Miami, Miller School of Medicine, Miami, Florida, USA.
Eduardo Edelman SaulDivision of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA.
Michele D StanchinaDivision of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA.
Mark K PolarDivision of Nuclear Medicine, Division of Radiology, University of Miami, Miller School of Medicine, Miami, Florida, USA.
Jennifer ChapmanDivision of Hematopathology, Department of Pathology, University of Miami, Miller School of Medicine, Miami, Florida, USA.
Wei ZhaoBiostatistics and Bioinformatics Shared Resource, Sylvester Comprehensive Cancer Center, Miami, Florida, USA.
Rafael Hennemann SassiDivision of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA.ORCID 0009-0009-9002-6426
Craig H MoskowitzDivision of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA.
Isildinha M ReisBiostatistics and Bioinformatics Shared Resource, Sylvester Comprehensive Cancer Center, Miami, Florida, USA.
Izidore S LossosDivision of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA.ORCID 0000-0002-9346-9013

Funding

Tumor Biology Research ProgramP30CA240139 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Stephen D. Nimer · 2019 to 2026
$24.1M
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study (Supplement)U01CA195568 · NCI · MAYO CLINIC ROCHESTER · PI CERHAN, JAMES R, FLOWERS, CHRISTOPHER R · 2015 to 2025
$22.1M
Identify the Mechanisms of LMO2-Mediated Inhibition of Homologous Recombination and Establish PARP-Targeted Synthetic Lethality as a New Therapy for DLBCLR01CA233945 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LOSSOS, IZIDORE S, VERDUN, RAMIRO ERNESTO · 2019 to 2023
$1.8M
Department of Defense Congressionally Directed Medical Research Programs Impact Award CA220385Dwoskin and Anthony Rizzo Families FoundationsJaime Erin Follicular Lymphoma Research ConsortiumNCI NIH HHS P30 CA240139NCI NIH HHS R01 CA233945NCI NIH HHS R01CA233945NCI NIH HHS U01 CA195568Peykoff Initiative from the Lymphoma Research FoundationSylvester Comprehensive Cancer Center National Cancer Institute P30CA240139
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Lymphoma, B-Cell, Marginal ZonePositron Emission Tomography Computed TomographyAdultAgedAged, 80 and overFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedNeoplasm StagingRadiopharmaceuticalsRetrospective StudiesFluorodeoxyglucose F18Radiopharmaceuticalsextranodal marginal zone lymphomaPET/CTstaging

Identifiers

PMID40396679
PMCPMC12232532

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.